What Is Atea Pharmaceuticals, Inc. (AVIR) Worth in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Atea Pharmaceuticals, Inc.'s intrinsic value is estimated at a composite fair value of $4.47. Trading at $4.86, the stock is approaching fair value or slight overvaluation (implied return of -8.0%), as 5 of 8 models suggest limited further upside. The most optimistic model, First Chicago, places fair value at $10.10 (+107.8%), while ML-RIV — the most conservative — estimates $0.59 (-87.9%). This +195.7% gap reflects genuine analytical uncertainty about Atea Pharmaceuticals, Inc.'s intrinsic worth.
What Do the Models Say About AVIR?
8 of 13 models are currently active for AVIR. Of these, 2 models suggest upside while 6 models suggest overvaluation. The Bayesian DCF estimates AVIR's intrinsic value at $1.96, implying -59.6% downside from the current price. See which stocks rank higher →
How Does AVIR Rank in Biotechnology?
Among 76 Biotechnology stocks, AVIR ranks #48 by Quality of Company score. CirclFi's QOC score of 4.6/10 evaluates 32 fundamental signals. A score of 4.6 reflects mixed fundamentals.
See all Most Undervalued Biotechnology Stocks →
The Biotechnology sector introduces analytical considerations specific to biotech businesses. For Atea Pharmaceuticals, Inc., metrics like clinical trial success rate provide important context that general-purpose valuation models may underweight.
Is AVIR a Value Trap?
CirclFi's Value Trap algorithm assigns AVIR a score of 18/100 (SAFE). This indicates minimal risk. Fundamentals are healthy. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →
Multi-Model Methodology
8 of 13 models are active for Atea Pharmaceuticals, Inc.. Moderate coverage provides meaningful perspective. Each model applies a fundamentally different valuation philosophy. See the complete methodology →
According to the CirclFi Deep Alpha Valuation Engine, Atea Pharmaceuticals, Inc. scores 4.6 out of 10 on our 32-signal quality assessment, a moderate rating that shows mixed signals across our quality framework with notable weaknesses. The QOC score synthesizes profitability margins, revenue growth reliability, debt management, and capital allocation into a single metric designed to separate durable businesses from statistically cheap ones.
The gap between the most bullish and bearish model spans +195.7% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →
Data Sources & Confidence
Every AVIR valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →
Across AVIR's 8 active models, average confidence is 28%. Lower confidence may reflect limited history or high volatility.
CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →
Buy with Gumroad